Moderna, Inc. (MRNA) saw its stock price soar 5.06% during intraday trading on Tuesday, marking a significant upward movement for the mRNA vaccine maker.

The surge appears linked to investor optimism following a widely reported story about a tech executive who used AI tools like ChatGPT and Google's DeepFold to design a personalized cancer vaccine for his dog. Investment commentators highlighted that this real-world example showcases the emerging potential of "programmable medicine," a field where Moderna's mRNA technology is seen as a key enabler.

Further bolstering sentiment, recent regulatory developments were noted, including draft guidance from the U.S. Food and Drug Administration for targeted individualized therapies, which specifically referenced RNA-based treatments. This combination of a tangible AI-medicine breakthrough and a supportive regulatory environment for personalized therapies is driving positive reassessment of Moderna's long-term prospects in the evolving biotech landscape.